Rucaparib (PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.

Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4]

Rucaparib Phosphate (PF-01367338 phosphate) is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy.

Rucaparib (AG014699) camsylate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki=1.4 nM for PARP-1. Rucaparib camsylate is an inhibitor of hexose hexaphosphate dehydrogenase (H6PD). Rucaparib camsylate has the potential to be investigated in debulking resistant prostate cancer (CRPC) studies.

Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4].

Rucaparib (AG014699) tartrate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) and acts on PARP-1 (Ki: 1.4 nM).Rucaparib tartrate is a hexose hexaphosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has potential for use in the study of destructive resistant prostate cancer (CRPC).

Rucaparib monocamsylate (Rucaparib Camsylate) is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains.